Candriam S.C.A. Boosts Stake in Chemed Corporation $CHE

Candriam S.C.A. lifted its holdings in shares of Chemed Corporation (NYSE:CHE) by 23.1% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 55,609 shares of the company’s stock after purchasing an additional 10,431 shares during the quarter. Candriam S.C.A. owned about 0.38% of Chemed worth $27,079,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Creekmur Asset Management LLC purchased a new stake in shares of Chemed in the 2nd quarter valued at approximately $28,000. SVB Wealth LLC acquired a new stake in Chemed in the 1st quarter valued at approximately $30,000. WPG Advisers LLC purchased a new stake in Chemed in the first quarter valued at approximately $32,000. Parkside Financial Bank & Trust raised its position in Chemed by 86.3% in the second quarter. Parkside Financial Bank & Trust now owns 95 shares of the company’s stock valued at $46,000 after purchasing an additional 44 shares during the period. Finally, Geneos Wealth Management Inc. lifted its stake in Chemed by 330.4% during the first quarter. Geneos Wealth Management Inc. now owns 99 shares of the company’s stock worth $61,000 after purchasing an additional 76 shares in the last quarter. 95.85% of the stock is currently owned by hedge funds and other institutional investors.

Chemed Stock Performance

Shares of CHE opened at $445.87 on Friday. Chemed Corporation has a 1 year low of $408.42 and a 1 year high of $623.60. The stock has a market capitalization of $6.32 billion, a PE ratio of 23.58, a PEG ratio of 2.69 and a beta of 0.43. The stock has a 50-day simple moving average of $444.58 and a 200-day simple moving average of $485.06.

Chemed (NYSE:CHE) last released its earnings results on Tuesday, October 28th. The company reported $5.27 earnings per share for the quarter, missing analysts’ consensus estimates of $5.39 by ($0.12). Chemed had a return on equity of 25.89% and a net margin of 11.02%.The firm had revenue of $624.90 million for the quarter, compared to analysts’ expectations of $626.04 million. During the same quarter in the previous year, the company posted $5.64 earnings per share. The firm’s quarterly revenue was up 3.1% on a year-over-year basis. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. Analysts predict that Chemed Corporation will post 21.43 EPS for the current year.

Chemed Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 5th. Stockholders of record on Monday, November 17th will be given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Monday, November 17th. Chemed’s payout ratio is 12.69%.

Insider Buying and Selling at Chemed

In related news, CEO Kevin J. Mcnamara sold 3,000 shares of the business’s stock in a transaction on Friday, September 26th. The shares were sold at an average price of $461.28, for a total transaction of $1,383,840.00. Following the completion of the transaction, the chief executive officer owned 96,197 shares in the company, valued at approximately $44,373,752.16. The trade was a 3.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Patrick P. Grace sold 150 shares of the stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $463.39, for a total value of $69,508.50. Following the completion of the transaction, the director directly owned 3,397 shares in the company, valued at $1,574,135.83. This trade represents a 4.23% decrease in their position. The SEC filing for this sale provides additional information. 3.29% of the stock is currently owned by insiders.

Analysts Set New Price Targets

CHE has been the subject of a number of research reports. Bank of America dropped their price objective on Chemed from $610.00 to $595.00 and set a “buy” rating for the company in a research note on Wednesday, September 10th. Zacks Research raised Chemed from a “strong sell” rating to a “hold” rating in a research report on Thursday, October 30th. Jefferies Financial Group upgraded shares of Chemed from a “hold” rating to a “buy” rating and boosted their price target for the stock from $490.00 to $550.00 in a research note on Tuesday, September 2nd. Royal Bank Of Canada lowered their price objective on shares of Chemed from $589.00 to $572.00 and set an “outperform” rating for the company in a research note on Monday. Finally, Oppenheimer cut their target price on shares of Chemed from $650.00 to $580.00 and set an “outperform” rating on the stock in a research note on Thursday, July 31st. Four analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Chemed has an average rating of “Moderate Buy” and a consensus price target of $574.25.

Chemed Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.